SCHEMBL18128802

SCHEMBL18128802

CN(C)c1ccc(S(=O)(=O)N2CCC[C@H]2c2ccccc2-c2cncn2CCc2ccc(F)cc2)cn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 2/20 0.38
CYP11B2 P19099 1/20 0.35
ATM Q13315 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CASP3 P42574 2/20 0.35
CASP7 P55210 2/20 0.35
KDM4E B2RXH2 4/20 0.34
ALDH1A1 P00352 3/20 0.34
KMT2A Q03164 1/20 0.34
LMNA P02545 3/20 0.34
FKBP1A P62942 2/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
IDO1 P14902 1/20 0.33
CYP2B6 P20813 1/20 0.33
HTR1A P08908 1/20 0.33
HTR7 P34969 1/20 0.33
HPGD P15428 1/20 0.33
MCOLN3 Q8TDD5 1/20 0.33
NLRP3 Q96P20 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16731030 1.00 TRPA1 (0.38) TRPA1CYP11B2ATMSMN1; SMN2CASP3
SCHEMBL18128806 0.85 LMNA (0.36) TRPA1CYP11B2SMN1; SMN2CASP3CASP7
SCHEMBL16719035 0.85 ALDH1A1 (0.39) TRPA1CYP11B2SMN1; SMN2CASP3CASP7
SCHEMBL16731956 0.85 LMNA (0.36) TRPA1CYP11B2SMN1; SMN2CASP3CASP7
SCHEMBL16719057 0.84 CYP11B2 (0.41) TRPA1CYP11B2FKBP1ACYP3A4CYP2D6
SCHEMBL18128796 0.84 CYP11B2 (0.41) TRPA1CYP11B2FKBP1ACYP3A4CYP2D6
SCHEMBL16720941 0.83 ALDH1A1 (0.42) TRPA1CYP11B2CASP3CASP7ALDH1A1
SCHEMBL18128803 0.83 GAA (0.44) TRPA1CYP11B2SMN1; SMN2KDM4ELMNA
SCHEMBL16718984 0.83 GAA (0.44) TRPA1CYP11B2SMN1; SMN2KDM4ELMNA
SCHEMBL20169615 0.82 ALDH1A1 (0.39) TRPA1CYP11B2ATMSMN1; SMN2CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3068391-B1 ARYL LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG MERCK SHARP & DOHME (US) 2018-05-23 EP disclosed
US-9975888-B2 Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug MERCK SHARP & DOHME CORP. (US) 2018-05-22 US disclosed
US-20160297809-A1 ARYL LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG MERCK SHARP & DOHME CORP. (US) 2016-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297809-A1 ARYL LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG CYP3A43, CYP3A5, CYP3A4 TRPA1 2594/4885CYP11B2 30/4885ATM 2892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.